
Conference Coverage
Latest Content

SONO 2026: Donna Catamero on Defining Cure as Myeloma Outcomes Improve

ESMO and EONS 2026: Workforce and Therapy Takeaways for Oncology Nurses

Oral Giredestrant Shifts Care Home: How Nurses Can Support Adherence

Nurses Are Key to Keeping Complex Cancer Care Close to Home

Chris Draft: Nurses Translate a Lung Cancer Diagnosis Into a Game Plan

Shorts










Videos
All News

The supplement, sold in Europe as OnLife, was evaluated in the single-arm STEFANO study of 146 patients with paclitaxel- or oxaliplatin-induced CIPN.

The evERA principal investigator explains ESR1 testing, bradycardia and stomatitis prevention, and oral adherence with giredestrant plus everolimus.

Beth Sandy, MSN, CRNP, FAPO, reviewed ADCs, immunotherapy, and targeted therapy in NSCLC with a focus on what nurses should monitor.

Neladalkib produced response rates of 49% after alectinib and 32% after multiple ALK TKIs plus chemotherapy in the ALKOVE-1 trial.

JoAnne Page, RN, a breast cancer survivor, shares what oncology nurses can do for care partners of patients with bladder cancer.

Giredestrant (Wilserdly) plus everolimus nearly doubled median PFS vs standard endocrine therapy plus everolimus in ESR1-mutated disease in evERA.

Alembic's generic binimetinib, in 15 mg and 45 mg tablets, is therapeutically equivalent to Mektovi for BRAF-mutant melanoma and NSCLC.

The field of oncology continues to evolve, driven by novel drug approvals, innovative delivery technologies, and emerging care strategies in cancer survivorship.

Pertuzumab-qcay is the second FDA-approved biosimilar to Perjeta, but a settlement with Genentech delays its US launch until Q3 2028.

The FDA declined to approve ivonescimab plus chemotherapy after EGFR TKI therapy, citing no statistically significant OS gain in HARMONi.

Cancer care teams are supporting more patients than ever, and oncology teams are navigating the clinical and operational realities that come with that growth.

A 5-decade SEER analysis found 5-year survival in young patients rose from 60% to 90%, yet non-Hispanic Black patients fared worst across cancers.

Nurses earn public trust through quiet acts of compassion, reassurance, and presence — a vital lifeline especially in oncology care.

Modeling projects anthracycline recipients may lose a median 9.4 life-years to age acceleration, a finding with survivorship care implications.

Oncology NPs and PAs are key to closing workforce gaps. Here’s how generalist, specialist, and hybrid APP models improve access and outcomes.
























































































